Washington D.C., June.10, 2024- Global Alzheimer’s Platform Foundation® (GAP) –applauds the U.S. Food and Drug Administration (FDA)’s acceptance of Eisai’s application for the subcutaneous maintenance dosing of Leqembi. With an action date set for January 25, 2025, this autoinjector will be used for weekly maintenance dosing and stands to reduce the burden on patients who are eligible to receive this disease-modifying therapy, as it can be used at home or at a broader array of medical facilities.
John Dwyer, President of the Global Alzheimer’s Platform Foundation stated, “We welcome the FDA’s acceptance of Eisai’s application for Leqembi’s subcutaneous weekly maintenance dosing. If approved, this technology will reduce patient burden and greatly improve access to this disease-modifying therapy for people across the country. Anything that can be done to swiftly ensure that more people have equal access to Leqembi, is a step in the right direction.”